15 results found.

Rhinitis, Allergic, Perennial, or Rhinitis, Allergic, Nonseasonal Clinical Trial using MK-8237 tablets; Placebo tablets; Rescue Medication: Self-Injectable Epinephrine; Rescue Medication: Loratadine tablets; Rescue Medication: Olopatadine ophthalmic drops; Rescue Medication: Mometasone furoate nasal spray

Merck Sharp & Dohme Corp. - Recruiting 12 years or older.
- A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001-00).
MK-8237 tablets; Placebo tablets; Rescue Medication: Self-Injectable Epinephrine; Rescue Medication: Loratadine tablets; Rescue Medication: Olopatadine ophthalmic drops; Rescue Medication: Mometasone furoate nasal spray

Allergic Rhinitis, or Allergic Rhinoconjunctivitis Clinical Trial using MK-8237; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 55 years.
- A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis.
MK-8237; Placebo

Allergic Rhinitis, Perennial Allergic Rhinitis, or Non-seasonal A Clinical Trial using AGR tablet; Placebo (for AGR tablet and/or Active Comparator); Active Comparator

Ahn-Gook Pharmaceuticals Co.,Ltd - Recruiting 12 years or older.
- A 4 Week Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of AGR Tablet in the Treatment of Perennial Allergic Rhinitis in Korean : a Phase III Clinical Trial Bridging Study.
AGR tablet; Placebo (for AGR tablet and/or Active Comparator); Active Comparator

Seasonal Allergic Rhinitis, or Asthma Clinical Trial using Ragweed-SPIRE; Placebo

Circassia Limited - Recruiting 18 years to 65 years.
- A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis.
Ragweed-SPIRE; Placebo

Seasonal Allergic Rhinitis Clinical Trial using Ragweed-SPIRE; Placebo

Circassia Limited - Recruiting 18 years to 65 years.
- A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Four Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.
Ragweed-SPIRE; Placebo

Seasonal Allergic Rhinitis Clinical Trial using acupressure pellets

University of Mississippi Medical Center - Recruiting 18 years or older.
- Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis.
acupressure pellets

Asthma, or Allergic Rhinitis Clinical Trial using Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo; Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase; QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo; QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris; Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase; Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris

West Penn Allegheny Health System - Recruiting 12 years to 15 years.
- A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis.
Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo; Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase; QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo; QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris; Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase; Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris

Allergic Rhinitis Due to Grass Pollens Clinical Trial using Grazax; Placebo

ALK-Abell¢ A/S - Recruiting 18 years to 65 years.
- Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate.
Grazax; Placebo

Allergic Rhinitis Clinical Trial

Istanbul University - Recruiting 18 years to 70 years.
- Long Term Follow up in Patients Using Immunotherapy: Efficacy and Impact on Quality of Life.

Allergic Rhinitis Clinical Trial using Grazax; Grazax Placebo

Imperial College London - Recruiting 18 years to 65 years.
- Randomised Placebo-controlled Study of Grass Pollen Allergen Immunotherapy Tablet (AIT) for Seasonal Rhinitis: Time Course of Nasal, Cutaneous and Immunological Outcomes.
Grazax; Grazax Placebo

Asthma and Allergic Rhinitis Clinical Trial using Montelukast; Montelukast sodium

PharmaKing - Recruiting 20 years to 45 years.
- A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulairr (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects.
Montelukast; Montelukast sodium

Rhinitis, Allergic, Perennial and Seasonal Clinical Trial using fluticasone furoate group

GlaxoSmithKline - Recruiting 2 years or older.
- An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamysr Administered in Korean Patients According to the Prescribing Information.
fluticasone furoate group

Allergic Rhinitis Clinical Trial using QAW039; Montelukast; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber.
QAW039; Montelukast; Placebo

Bronchial Asthma, or Allergic Rhinitis Clinical Trial using sublingual house dust mites allergen extract; placebo in sublingual applicator

Medical Universtity of Lodz - Recruiting 6 years to 18 years.
- Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites.
sublingual house dust mites allergen extract; placebo in sublingual applicator

Rhinitis, Allergic, Perennial Clinical Trial using EWO1

China Medical University Hospital - Recruiting 12 years or older.
- A Double-Blind, Randomized Parallel Group, Placebo-Control Study of EW01 in Persistent Allergic Rhinitis (PAR) Patients.
EWO1